Sitagliptin phosphate hydrate is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used in the clinical management of type 2 diabetes mellitus to improve glycemic control. To ensure regulatory compliance… Read more






Sitagliptin phosphate hydrate is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used in the clinical management of type 2 diabetes mellitus to improve glycemic control. To ensure regulatory compliance and therapeutic safety, pharmaceutical laboratories require high-quality reference standards of the active ingredient, along with its associated impurities and related compounds. This collection facilitates rigorous impurity profiling, allowing for the precise identification and quantification of process-related impurities, desfluoro analogues, and enantiomeric forms that may arise during synthesis. Furthermore, the availability of stable isotope labelled compounds and other critical reference materials supports the development and validation of sensitive analytical methods, ensuring the accuracy of stability testing and quality control protocols throughout the drug product lifecycle.